ERCC1和Pim-1表达与非小细胞肺癌化疗疗效的相关性  

The association of ERCC1 and Pim-1 with chemotherapeutic effectiveness in NSCLC

作　　者：梁绪中 刘合代[2] 倪裕丰[2] 丁昭珩[3] 姜峰[2] 李文霞 丁罡[2] 

机构地区：[1]定西市人民医院药剂科,甘肃定西743000 [2]上海交通大学医学院附属新华医院崇明分院肿瘤科(科研中心),上海202150 [3]上海市普陀区人民医院肿瘤科,上海200060

出　　处：《现代肿瘤医学》2015年第22期3242-3245,共4页Journal of Modern Oncology

基　　金：上海市崇明县科学技术委员会科学技术基金资助项目(编号:CK2010-28)

摘　　要：目的:探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)患者肺癌组织标本中ERCC1和Pim-1的表达与临床特征及化疗疗效的相关性。方法:对我院病理确诊的70例NSCLC患者肿瘤组织,通过实时定量荧光PCR法检测ERCC1和Pim-1基因mRNA表达水平,回顾性分析ERCC1和Pim-1基因表达与临床病理关系、铂类化疗疗效和总生存情况。结果:70例NSCLC患者肿瘤组织中ERCC1和Pim-1高表达患者比率分别为37.14%(26/70)和61.43%(43/70),ERCC1高表达与性别、吸烟史、组织类型、TNM分期均无关(P>0.05),Pim-1高表达与性别、吸烟史相关(P<0.05),而与组织类型、TNM分期无关(P>0.05)。ERCC1和Pim-1共同高表达率为20.00%(14/70)。ERCC1高表达组患者化疗有效率(19.23%,5/26)显著低于低表达组患者(47.73%,21/44)(P<0.05)。Pim-1高表达组患者化疗有效率(34.88%,15/43)和低表达组患者(40.74%,11/27)无统计学差异(P>0.05)。ERCC1和Pim-1高表达组的中位生存期(median survival time,MST)为27个月和24个月低于低表达组的33个月和27个月,但无统计学差异(P>0.05)。结论:NSCLC患者中ERCC1低表达组患者化疗有效率和存活率高,是化疗受益的指标。Objective： To investigate the relationship of the expression of ERCC1 and Pim-1 with the clinical factors and chemotherapeutic efficacy in patients with NSCLC. Methods： Seventy cases with NSCLC pathologically proven were analyzed retrospectively. The mRNA expressions of ERCC1 and Pim-1 were detected by Real-time quantitative PCR（ RT-QPCR）. The clinical factors and platinum-based chemotherapeutic efficacy in lung canser patients were observed. Results： The expression rates of ERCC1 and Pim-1 in patients with NSCLC were 37. 14%（ 26 /70）and 61. 43%（ 43 /70）. The expression of ERCC1 was not related to gender,smoking,histological type,TNM stage（ P 0. 05）. The expression of Pim-1 was not related to histological type,TNM stage（ P 0. 05）,but it was related to gender,smoking. The co-overexpression of ERCC1 and Pim-1 in ESCLC patients was 20. 00%（ 14 /70）. The patients with low expression of ERCC1 showed increased effective rate of chemotherapy compared to ERCC1 overexpression group. No significant difference of chemotherapeutic effectiveness was found between the patients with low（ 34. 88%,15 /43） and high（ 40. 74%,11 /27） expression of Pim-1. The median survival times of the patients with high expression of ERCC1 or Pim-1 were lower than the patients with low expression of ERCC1 and Pim-1,but the difference was not statistically significant（ P 0. 05）. Conclusion： The patients with low expression of ERCC1 showed higher effectiveness of chemotherapy and survival rate,which indicates that the expression of ERCC1 is related to tumor biological behivor.

关 键 词：非小细胞肺癌 疗效 ERCC1 PIM-1 化疗有效率 

分 类 号：R734.2[医药卫生—肿瘤]